Table 5 Association of PLS3 expression with clinicopathological features in PDA patients from TCGA
Variables | Cases (number, %) | PLS3 level (number, %) | P | |
|---|---|---|---|---|
High expression N = 83 | Low expression N = 84 | |||
Age (years) | ||||
 ≤ 55 | 33 (19.8) | 20 (60.6) | 13 (39.4%) | 0.16 |
 > 55 | 134 (80.2) | 63 (47.0) | 71 (53.0) | |
Histologic grade | ||||
 G1/G2 | 117 (70.1) | 57 (48.7) | 60 (51.3) | 0.69 |
 G3/G4 | 50 (29.9) | 26 (52.0) | 24 (48.0) | |
N classification | ||||
 N0 | 47 (28.1) | 20 (42.6) | 27 (57.4) | 0.24 |
 N1 | 120 (71.9) | 63 (52.5) | 57 (47.5) | |
T classification | ||||
 T1/T2 | 28 (16.8) | 12 (42.9) | 16 (57.1) | 0.42 |
 T3/T4 | 139 (83.2) | 71 (51.1) | 68 (48.9) | |
Gender | ||||
 Female | 76 (45.5) | 37 (48.7) | 39 (51.3) | 0.81 |
 Male | 91 (54.5) | 46 (50.5) | 45 (49.5) | |
Stage | ||||
 Stage I/II | 160 (95.8) | 79 (49.4) | 81 (50.6) | 0.68 |
 Stage III/IV | 7 (4.2) | 4 (57.1) | 3 (42.9) | |